Medical literature monitoring is a key part of pharmacovigilance (PV) and ultimately patient safety across the lifecycle of a medicine. Globally, the practice is relatively straightforward, but up to now, screening local literature has been a highly resource-intensive activity yielding modest, if vital, findings. That smart automation might alleviate the burden comes as a huge relief, especially as product development ambitions grow and PV process innovation becomes essential to control costs. Biologit’s Jean Redmond explains.
read more